Myles Minter
Stock Analyst at William Blair
(1.56)
# 3,162
Out of 4,711 analysts
18
Total ratings
60%
Success rate
-2.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Initiates: Outperform | n/a | $5.20 | - | 1 | Nov 5, 2024 | |
| ARGX argenx SE | Upgrades: Outperform | n/a | $623.82 | - | 2 | Nov 1, 2024 | |
| KRRO Korro Bio | Initiates: Outperform | n/a | $43.67 | - | 1 | Aug 14, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | n/a | $10.85 | - | 1 | Oct 10, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Outperform | $71 | $15.48 | +358.66% | 1 | Jul 24, 2023 | |
| MRNA Moderna | Initiates: Market Perform | n/a | $39.39 | - | 1 | Jul 24, 2023 | |
| VRTX Vertex Pharmaceuticals | Initiates: Outperform | n/a | $397.27 | - | 1 | May 30, 2023 | |
| PRAX Praxis Precision Medicines | Downgrades: Market Perform | n/a | $76.52 | - | 2 | Mar 6, 2023 | |
| LRMR Larimar Therapeutics | Upgrades: Outperform | n/a | $4.01 | - | 3 | Sep 19, 2022 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Outperform | n/a | $245.44 | - | 1 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $35.63 | - | 2 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.86 | - | 1 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $116 | $135.42 | -14.34% | 1 | Feb 24, 2020 |
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.20
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $623.82
Upside: -
Korro Bio
Aug 14, 2024
Initiates: Outperform
Price Target: n/a
Current: $43.67
Upside: -
Neumora Therapeutics
Oct 10, 2023
Initiates: Outperform
Price Target: n/a
Current: $10.85
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $15.48
Upside: +358.66%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $39.39
Upside: -
Vertex Pharmaceuticals
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $397.27
Upside: -
Praxis Precision Medicines
Mar 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $76.52
Upside: -
Larimar Therapeutics
Sep 19, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.01
Upside: -
Alnylam Pharmaceuticals
Jun 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $245.44
Upside: -
Dec 14, 2021
Upgrades: Outperform
Price Target: n/a
Current: $35.63
Upside: -
Sep 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.86
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: $116
Current: $135.42
Upside: -14.34%